Dr. Garcia-Manero on Deferasirox in Iron Chelation Therapy for MDSMay 7th 2015
Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses deferasirox (Exjade) in iron chelation therapy for patients with myelodysplastic syndromes (MDS).
Dr. Gail Roboz on Molecular Mutations in MDSMay 2nd 2015
Gail J. Roboz, MD, associate professor of Medicine, director, Leukemia Program, Weill Medical College of Cornell University, New York-Presbyterian Hospital, discusses the growing field of molecular mutations in myelodysplastic syndromes (MDS).
Dr. Zeidan on Subsequent MDS in Prostate Cancer Patients After RadiotherapyMay 2nd 2015
Amer Zeidan, MBBS, MHS, assistant professor of Medicine, Hematology, Yale Cancer Center, discusses a population-based study of subsequent myelodysplastic syndromes (MDS) in prostate cancer patients after radiotherapy.
T-Cell Depleted Allografts Lessen GVHD in MDSMay 1st 2015
Treatment with T-cell depleted transplantation was associated with a lower incidence of acute graft versus host disease (GVHD) and a very low incidence of chronic GVHD compared with unmodified allografts in patients with advanced myelodysplastic syndrome.
Sara Tinsley Discusses Quality of Life in Patients with High-Risk MDSMay 1st 2015
Sara M. Tinsley, MS, PhD, ARNP, AOCN, nurse practitioner, malignant hematology, Moffitt Cancer Center, discusses a study that examined quality of life in patients with high-risk myelodysplastic syndromes (MDS).
Dr. Garcia-Manero on Rigosertib in Patients with High-Risk MDS After Failure of Hypomethylating AgentsApril 30th 2015
Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the multikinase inhibitor rigosertib in patients with MDS who have failed hypomethylating agents.
Sotatercept Effectively Treats Anemia in MDS and Non-Proliferative CMMLApril 30th 2015
The first-in-class activin receptor antagonist sotatercept stimulated erythropoiesis in nearly half of patients with MDS and non-proliferative CMML following failure on erythropoiesis-stimulating agents.